Physician profile
Bogdan Orasanu
NPI 1790809010
$3,689.06
in general payments reported to CMS, 2019-2025
14 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $1,358 · 2021: $348 · 2022: $146 · 2023: $646 · 2024: $449 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,919.10 | 2019-2025 | Axonics, Solyx Sis System, Advantage System |
| Medtronic, INC. | $814.94 | 2021-2025 | Interstim, Altaviva |
| Astellas Pharma US INC | $291.36 | 2019-2023 | Myrbetriq |
| Axonics, INC. | $240.86 | 2021-2024 | Axonics, Bulkamid |
| Medtronic USA, INC. | $102.07 | 2019-2020 | |
| Pfizer INC. | $93.55 | 2019-2021 | |
| Caldera Medical, INC | $49.39 | 2023 | Desara |
| Allergan, INC. | $41.21 | 2019-2021 | |
| Urovant Sciences INC | $40.65 | 2022 | |
| Abbvie INC. | $26.48 | 2023 | |
| Sumitomo Pharma America, INC. | $21.45 | 2025 | Gemtesa |
| Abbott Laboratories | $18.27 | 2021 | |
| Conmed Corporation | $16.78 | 2024 | Airseal |
| Coopersurgical, INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bogdan Orasanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.